Fig. 3: Progression free and overall survival for patients treated with platinum-basedchemotherapy. | npj Breast Cancer

Fig. 3: Progression free and overall survival for patients treated with platinum-basedchemotherapy.

From: Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing

Fig. 3: Progression free and overall survival for patients treated with platinum-basedchemotherapy.The alternative text for this image may have been generated using AI.

A, B Kaplan–Meier curve of overall survival (A) and progression free survival (B) for patients treated with platinum-based chemotherapy, according to BRCA 1/2 mutated and HRD score level. Black curves: whole cohort, red curves: patients with BRCA mutated tumors, green curves: patients with BRCA WT HRD-high tumors, blue curves: patients with BRCA WT HRD- low tumors. Ticks denote censored data. C, D Kaplan–Meier curve of overall survival (C) and progression free survival (D) for patients treated with platinum-based chemotherapy, according to BRCA 1/2 mutated and S3 level. Black curves: whole cohort, red curves: patients with BRCA mutated tumors, green curves: patients with BRCA WT S3-high tumors, blue curves: patients with BRCA WT S3-low tumors. Ticks denote censored data.

Back to article page